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ABSTRACT: Our previous studies have shown that the nonste-
roidal anti-inﬂammatory drug indomethacin exhibits antileukemic
activity in vitro and can inhibit the aldo-keto reductase AKR1C3,
which we identiﬁed as a novel target in acute myeloid leukemia.
However,theantileukemicactionsofindomethacinarelikelytobe
complex and extend beyond inhibition of either AKR1C3 or
cycloxygenases. To further understand the antileukemic activity
ofindomethacinwehaveuseduntargetednuclearmagneticresonance-
basedmetabolicanalysistocharacterizetheresponsesofKG1aand
K562 cell lines in both normal culture conditions and in hypoxia,
which better represents the tumor environment in vivo. Hypoxia
induced dramatic metabolic changes in untreated KG1a and K562, including adaptation of both phospholipid and glycolytic
metabolism. Despite these changes, both cell lines sustained relatively unaltered mitochondrial respiration. The administration of
indomethacin induced similar metabolic responses regardless of the oxygen level in the environment. Notable exceptions included
metabolitesassociatedwithdenovofattyacidsynthesisandcholinephospholipidmetabolism.Collectively,theseresultssuggestthat
leukemia cells have the inherent ability to tolerate changes in oxygen tension while maintaining an unaltered mitochondrial
respiration. However, the administration of indomethacin signiﬁcantly increased oxidative stress in both KG1a and K562, inducing
mitochondrial dysfunction, regardless of the oxygenation conditions. These ﬁndings emphasize the particular pertinence of the
tricarboxylic acid cycle to the survival of cancer cells and may explain why some antileukemic drugs have been discovered and
developed successfully despite the use of culture conditions that do not reﬂect the hypoxic environment of cancer cells in vivo.
S
everal studies have highlighted potential roles for the aldo-
keto reductase 1C3 (AKR1C3) in the etiology
1-5 and patho-
physiology of cancer,
6,7 fostering interest in generating selective
AKR1C3 inhibitors as potential chemopreventive and che-
motherapeutic agents.
8-11 Our interest in the role of AKR1C3
in acute myeloid leukemia (AML) arose from studies of the in
vitro antileukemic activity of the nonsteroidal inﬂammatory drug
(NSAID) indomethacin, which we discovered to include inhibi-
tion of AKR1C3.
1,6,11 We later published crystal structures of
indomethacin bound to AKR1C3, and consequently drug devel-
opment studies have used indomethacin as a starting point for
AKR1C3 inhibitor design.
8-10 The antileukemic actions of
indomethacin are likely to be complex and extend beyond inhi-
bition of either AKR1C3 or cycloxygenases. Nuclear magnetic
resonance (NMR) spectroscopy is a commonly used analytical
method that provides unique insight into the composition of
small metabolites, that is, the metabolome, of cellular model
systems as well as human and animal bioﬂuids and tissues.
12-15
We have therefore used this approach here to investigate the
metabolic eﬀects of indomethacin treatment on two myeloid
leukemia cell lines (K562 and KG1a).
Importantly,ourpreviousstudiesoftheactionsofindometha-
cin against myeloid leukemia cells used conventional culture
conditions that do not reﬂect the hypoxic conditions present in
themalignantbonemarrow.Evidenceexiststhatreducedoxygen
tension aﬀects cellular metabolism and the microenvironment,
including pH level.
16-20 For example, glycolysis is enhanced in
hypoxia via the increased activity of glucose transporters and
glycolytic enzymes, ultimately inducing an increased lactate pro-
duction and decreased pH levels.
16,21 These and other modula-
tions in metabolite concentrations induced by hypoxia can aﬀect
the response to pharmacological treatment.
17 Therefore here we
utilize NMR-based metabolic proﬁling to study the impact of
indomethacin treatment on the metabolism of K562 and KG1a
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myeloid leukemia cell lines with the aims of gaining further
mechanisticinsightintotheantileukemicactivitiesofthisdrugas
well as the eﬀects of the local environment on the outcome of
treatment. To achieve the latter we investigated the eﬀects of
treatment both in standard culture conditions and in hypoxic
conditions, which better mimics the tumor microenvironment in
vivo. Furthermore, we utilized two cell lines that apoptose in
response to the drug in order to examine the generality of any
metabolic responses detected. Our ﬁndings demonstrate that
despite dramatic changes in the metabolome of myeloid cells
grown under conventional or hypoxic culture conditions the
tricarboxylic acid (TCA) cycle is relatively preserved. However,
in the presence of indomethacin, the TCA cycle becomes com-
monly deregulated independently of the prevailing oxygen ten-
sion.
’RESULTS AND DISCUSSION
Metabolic Changes Induced by Hypoxic Environment.
1H 2-dimensional J-resolved (J-RES) NMR spectra of extracts
ofKG1a andK562 AMLcelllines grown undereitherhypoxicor
normal culture conditionswererecorded.Wepreviouslyshowed
that the metabolic profiles of these two AML cell lines, when
grown in normal culture conditions, differ considerably.
14 Here
wedemonstrate(asshown,forKG1acells,intheNMRspectrain
Figure 1, panel a) that hypoxia induced marked changes in the
metabolic profiles of K562 and KG1a cell lines. Moreover,
regardless of the constitutive metabolic differences between
these two cell lines, the hypoxia-induced changes in the meta-
bolic profiles were strikingly similar between KG1a and K562.
Principal component analysis (PCA) was performed on the
projected J-RES NMR data sets of the two untreated cell lines
growninbothhypoxicandnormalconditions;theresultingPCA
scores plot (Supplementary Figure 1) highlights remarkable
differences between the metabolomes of K562 and KG1a cells
(almost 70% of the variability is captured by the first principal
component). The metabolic differences between the hypoxic
and normal culture environments, accounted for on PC2, com-
prise about a third of the variation described along PC1. The
metabolic variability within each of the 4 groups was minor
relative to the changes induced by cell type and oxygen condi-
tions in the culture.
Multiple univariate analyses (t tests) followed by a correction
for multiple hypothesis testing (false discovery rate, FDR
22)a t
the 1% level was performed on the J-RES NMR data sets after
noise exclusion (resulting in about 18,000 data points per data
set); speciﬁcally the hypoxic and normal culture condition data
sets for each cell line were compared. This conﬁrmed that the
vast majority of the detected metabolite peaks diﬀered signiﬁ-
cantly between the conditions of growth. The eﬀect of the hypoxic
environment on the metabolic proﬁles of K562 and KG1a AML
cells causes a signiﬁcantincrease in the concentrations of branched
amino acids (valine, leucine, and isoleucine), lactate, alanine,
creatine, phosphocreatine, glycerol-3-phosphate, glycerophospho-
choline, myo-inositol, uridine-50-diphospho-N-acetyl-glucos-
amine (UDP-GlcNAc), uridine-50-diphospho-N-acetyl-galactos-
amine (UDP-GalNAc), and phenylalanine. In contrast, proline,
phosphocholine,citrate,glutamate,glutathione,andaspartateare
signiﬁcantly decreased in cells grown in hypoxic conditions
(SupplementaryFigure2).Moreover,inbothcelllines,fumarate,
malate, and succinate are not signiﬁcantly diﬀerent betweencells
grown in hypoxic versus nonhypoxic conditions. Among all the
detected metabolites common to both cell lines, only the con-
centrations of sarcosine and glycine change in opposite direc-
tions,i.e.,incellsgrownunderhypoxicconditions.Bothmetabolites
have increased concentrations in K562 cells and decreased levels
in KG1a cells. Moreover, glutamine is present in detectable
amountsonlyinK562cells.Toassesstheextentofthesechanges
in a more quantitative manner,
1H 1D NMR spectra were col-
lected with a long repetition time to allow for full longitudinal
relaxationoftheprotons.TheconcentrationsofGSHandseveral
other metabolites involved in or related to the TCA cycle and to
choline metabolism for cells grown in either hypoxic or non-
hypoxic conditions are reported in Supplementary Figure 3.
Regardless of the constitutive diﬀerences between the two
AML cell lines, the metabolic alterations induced by the hypoxic
environmentarestrikinglysimilarinKG1aandK562cells.These
results suggest that both the AML cell lines adopt a common
adaptive mechanism when exposed to an environment with low
oxygen tension. In agreement with previous studies performed
on cell model systems, we observe an enhancement of the gly-
colytic activity (as conﬁrmed by an intracellular accumulation of
alanine and lactate) induced by the hypoxic environment.
18 This
is likely the outcome of the overexpression of glucose transpor-
ters (particularly GLUT1 and GLUT3) and an increased activity
of the glycolytic enzymes in hypoxia.
23,24 The increased expres-
sion of hypoxia-inducible factor (HIF) in hypoxic tumors has
been shown to trigger the expression of several glycolytic enzymes,
favoring the accumulation of lactate and carbonic acids resulting
in an increased acidity in the intracellular environment.
17,19,25
Interestingly, although glycolysis appears to be enhanced in
cells grown in hypoxia, the concentrations of metabolites within
the TCA cycle are, except for citrate, not signiﬁcantly altered.
Theseobservationsindicatethatadaptivemechanismsconserved
between the cell types serve to protect mitochondrial respiration
and thereby promote cell survival. Thestability of the TCA cycle
under reduced oxygen tension conditions is made yet more
noteworthy by the observed hypoxia-induced changes in other
pathways. Hypoxia altered several metabolites associated with
the biosynthesis and the catabolism of phospholipids and other
lipids(e.g.,citrateasaprecursorofdenovofattyacidsynthesis)in
both cell lines. The accumulation of phosphocreatine, a meta-
bolite recognized to function as a phosphagen and hence energy
reservoir for cells, is indicative of an adaptive response to an
enhanced energy metabolism in hypoxic cells.
18 The hypoxia-
induced decrease inphosphocholine and increase inglyceropho-
sphocholine concentrations have been attributed to a reduction
of phosphatidylcholine turnover,
18,26 opposite to what has been
reported for prostate cancer cell lines in hypoxia.
20 Similarly, the
accumulation of myo-inositol in AML cells under hypoxic
conditionsmightberelatedtothephosphatidylcholineturnover.
In fact, altered requirements of myo-inositol, an isomer of glucose
havingseveralimportantfunctionsinmammaliancells(e.g.,asan
osmolyte), have been associated with the modulation of phos-
pholipid levels.
27,28 Increased concentrations of metabolites of
thehexosaminepathwaycanbeattributedwiththeup-regulation
of glucose metabolism aﬀecting the synthesis of glycolytic
intermediates.
29-31 Metabolites in the hexosamine pathway,
such as UDP-GlcNAc and UDP-GalNAc, are important precur-
sors for the formation of N-glycans, and their elevation has been
related to response of several forms of cellular stress including
hypoxia.
31
TherelativestabilityoftheTCAcyclebetweendiﬀerentstates
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Figure 1. Metabolic diﬀerences induced by treatment with indomethacin in acute myeloid leukemia cell lines grown under nonhypoxic or hypoxic
conditions. a)
1H projected J-resolved NMR spectra acquired on the polar fraction of KG1a cell extracts grown either in nonhypoxic (green lines,
showing all 12 replicate spectra) or in hypoxic (∼1% oxygen; red line, showing all 6 replicate spectra) conditions. b) Loadings plot along PC2 obtained
fromtheprincipalcomponentanalysisofthe
1HNMRspectraacquiredontheintracellularextractsofKG1aandK562acutemyeloidleukemiacelllines
treated with indomethacin and grown in nonhypoxic or in hypoxic conditions. c) Scores plot obtained from the principal component analysis of the
1H NMR data sets of untreated (green symbols) and indomethacin-treated (red symbols) KG1a and K562 cells grown in hypoxic and nonhypoxic
conditions. d) Average concentrations of selected TCA cycle intermediates and reduced glutathione in untreated or indomethacin-treated KG1a and
K562 cells in nonhypoxic (average of 12 samples) or in hypoxic (average of 6 samples) conditions. e) Average concentrations of metabolites of the
cholinepathwayinuntreatedorindomethacin-treatedKG1aandK562cellsinnonhypoxic(averageof12samples)orinhypoxic(averageof6samples)
conditions. f) Treatment with indomethacin induces the formation of reactive oxygen species in AML cells. Percent of ROS positive cells in untreated
andindomethacin-treatedKG1aandK562AMLcellsgrownandtreatedeitherinnonhypoxicorinhypoxicconditions,measuredusingﬂowcytometry.
(Phe, phenylalanine; Tyr, tyrosine; His, histidine; Fum, fumarate; UDP, uridine diphosphate; Lac, lactate; Ala, alanine; Cre, creatine; PCre, phospho-
creatine; Gly, glycine; Tau, taurine; m-Ino, myo-inositol; Cho, choline; PCho, phosphocholine; GPCho, glycerophosphocholine; Asp, aspartate; Asn,
asparagine; Suc, succinate; Glu, glutamate; Gln, glutamine; GSH, glutathione; Cit, citrate; Pro, proline; Ace, acetate; Val, valine; Ile, isoleucine; Leu,
leucine; *: p < 0.01; **: p < 0.0001).172 dx.doi.org/10.1021/cb900300j |ACS Chem. Biol. 2011, 6, 169–175
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metabolome, is interesting to consider since in other systems
hypoxia tends to down-regulate the TCA cycle.
32 Hemopoietic
stem cells (HSC) and progenitor cells are able to leave their
hypoxic niches in the bone marrow, enter into the normoxic
peripheral circulation, and rehome to the bone marrow. This
happens at a very low frequency but is exploited in transplant
medicine by the mobilization of high numbers of HSCs into the
periphery of donors using cytokine stimuli. These mobilized
stem cells then, when introduced to the recipient, again home
from the normoxic periphery into hypoxic niches in the patients’
marrow.Thustheabilitytotolerateexchangesofoxygentensions
is an inherent ability of HSCs and progenitor cells. This ability is
shared by AML blasts, which again proliferate in the bone
marrow but also accumulate in the periphery. Our data indicate
that despite prolonged culture in artiﬁcial conditions, KG1a and
K562 cells have retained this plasticity and provide novel insight
into the molecular mechanisms that permit this behavior.
Metabolic Changes Induced by a 24-h Treatment with
Indomethacin. Tissue culture studies using cell lines have been
widely used to study potential cancer treatments in vitro. Despite
numerous successes this approach is often criticized as being
flawedbecauseconventionalcultureconditionsdonotreflectthe
hypoxic environment of tumor cells. Here we addressed the
metabolic consequences of indomethacin treatment on two
AML cell lines under both normal and arguably more realistic
hypoxicconditions.PCAwasperformedontheNMRdatasetsof
the AML cell lines, with and without indomethacin treatment,
grown under both hypoxic and nonhypoxic conditions (loadings
and scores plots included in Figure 1, panels b and c). The
resulting PCA scores plot (PC1 vs PC2; Figure 1, panel c)
indicates that the separation between the indomethacin-treated
and untreated samples (within each cell line and oxygen level) is
muchsmallerthantheseparationcausedbythegeneticvariability
between cell types or by the oxygen tension. The extent of the
differences induced by the drug treatment can be better high-
lightedbyperformingaPCAoneachsubsetofNMRdatalimited
to one cell line and one oxygenation condition. The four scores
plots, comparing the control and indomethacin treatment data
sets for KG1a and K562 cells grown under hypoxic and non-
hypoxic conditions, are shown in Supplementary Figure 4. A
clear separation is observed between the solvent control and
indomethacin treated KG1a and K562 cells grown in both
hypoxic and nonhypoxic conditions.
The analysis of the associated PCA loadings plots (data not
shown explicitly) as well as the results of univariate analyses
(t tests with FDR correction at 5% signiﬁcance), coupled with a
visual interpretation of the NMR spectra, are summarized in the
biochemicalpathwaysdepictedinSupplementaryFigure5(treated
cells under nonhypoxic conditions) and Figure 2 (treated cells
under hypoxia). Both common and disparate treatment-induced
changes between the two cell lines and the conditions of growth
can be highlighted. For example, glutathione, creatine, and R-
ketoglutarate are all signiﬁcantly decreased after drug treatment
inbothcelllinesandinbothconditionsofgrowth.Concurrently,
succinate, fumarate, choline, glycerol-3-phosphate, alanine, UDP-
GlcNAc, and UDP-GalNAc all signiﬁcantly accumulate in both
Figure 2. Metabolic diﬀerences induced by treatment with indomethacin in acute myeloid leukemia cell lines grown in hypoxic conditions. Schematic
representation of the metabolic pathways showing the most relevant metabolic changes induced by treatment with indomethacin and common to both
KG1aandK562celllinesgrownunderhypoxicconditions.Metabolitesingreen/redhavesigniﬁcantlyincreased/decreasedconcentrationsinbothKG1a
andK562celllinestreatedwithindomethacinandgrowninahypoxicenvironment;metabolitesinblackaredetected/identiﬁedintheNMRspectrabut
change diﬀerently or non-signiﬁcantly in the two cell lines; metabolites in gray were not detected in the NMR spectra.173 dx.doi.org/10.1021/cb900300j |ACS Chem. Biol. 2011, 6, 169–175
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cell lines regardless of the oxygen level. However, changes in
citrate concentration follow opposite trends for cells grown in
hypoxicorinnonhypoxicconditions (inthehypoxiccells,citrate
signiﬁcantly accumulated in the drug treated vs untreated sam-
ples; in the nonhypoxic counterpart a signiﬁcant depletion of
citrate in the treated samples was observed). Similarly, the con-
centration changes of some metabolites involved in choline
metabolism are common to both the cell lines but diﬀer when
hypoxia and nonhypoxia data sets are compared. In fact, cells
treatedwithindomethacininanonhypoxicenvironmentshowan
accumulation of glycerophosphocholine and a decrease of phos-
phocholine, whereas the administration of the drug under hypoxic
conditions produces the opposite eﬀect. Some of these observa-
tions, in particular for metabolites involved in the TCA cycle or
choline metabolism, were quantiﬁed from the NMR spectra in
Figure 1, panels d and e.
The observed indomethacin-driven depletion of R-ketogluta-
rate and associated rise in succinate mirrored observations made
in our previous study where we demonstrated that combining
medroxyprogesterone acetate (MPA) with bezaﬁbrate (Bez), in
normal culture conditions, generated reactive oxygen species
(ROS).
33 Following earlier observations showing that ROS
directly converted R-ketoglutarate into succinate
34 and treat-
ment of KG1a cells with H2O2 recapitulated R-ketoglutarate
depletion and succinate accumulation, we concluded that the
ROS generated by combined MPA and Bez is the mechanism
that causes the derangement of the TCA cycle.
14 In the current
study we therefore measured induction of ROS upon treatment
with indomethacin (Figure 1, panel f). The drug treatment
inducedsigniﬁcant increases inROSin bothcell lines. Strikingly,
despite the cells being able to protect the TCA cycle under
conditions of low oxygen availability, indomethacin deregulated
the balance of TCA metabolites in both cell lines and in both
normal and hypoxic culture conditions. Moreover, all of the
observed responsesofTCAintermediates(withtheexceptionof
citrate) to indomethacin were consistent in both culture condi-
tions. The signiﬁcant depletion of R-ketoglutarate and the
concurrent accumulation of succinate and fumarate suggest a
partial truncation of the TCA cycle induced by the generation of
ROS triggered by the indomethacin treatment. The indometha-
cin-induced generation of ROS also relates to the observation
that reduced glutathione is depleted in the AML cells after treat-
ment at diﬀerent oxygen levels. Similar observations were pre-
viously reported by de Groot and colleagues.
35 The striking,
oxygen-dependent behavior of citrate seems to indicate that the
administration of indomethacin in combination with hypoxia
counters the eﬀect of hypoxia alone and points to an accumula-
tionofcitrateinthecytosolduetoahinderedsynthesisofdenovo
fatty acids, cholesterol, and isoprenoids through the conversion
of citrate to acetyl-CoA.
36 The accumulation of a pool of citrate
outside of the TCA cycle therefore colors the interpretation of
the indomethacin-induced eﬀects of this intermediate with the
mitochondria.
Not all indomethacin-induced changes were as consistent as
those observed in the TCA cycle. Treatment of cells in normal
cultureconditionsresultedinalterationsofcholinephospholipid
metabolismthatareingeneralagreementwithpreviousreports.
37,38
However, the administration of indomethacin to cells under
hypoxia induced disparate alterations to these metabolites.
Similar to the changes in citrate concentration these opposite
trendssuggestthattheanti-inﬂammatoryeﬀectsofindomethacin
on the inﬂammatory pathways depend on the oxygen levelinthe
culture environment. In colorectal tumor cells and in prostate
cancer cell lines, HIF-1 has been shown to up-regulate COX2.
39
Thus, it can be argued that in leukemia cell lines treatment with
indomethacin interferes with the eﬀect of hypoxia on the enzymes
regulating the choline phospholipid metabolism.
Implications for Drug Development. From a therapeutic
perspective the key observation made here is that the adminis-
tration of indomethacin significantly increased oxidative stress
via generation of ROS in both KG1a and K562 leukemia cells,
inducing mitochondrial dysfunction regardless of the oxygena-
tion conditions. These findings may emphasize the particular
pertinence of the TCA cycle to the survival of cancer cells and
may explain why some antileukemic drugs have been discovered
and developed successfully despite the use of culture conditions
thatdonotreflectthehypoxicenvironmentofcancercellsinvivo.
It is also noteworthy that indomethacin alone induced ROS, an
observation notseeninour earlier study using the lessAKR1C3-
selective inhibitor MPA.
14 This finding lends support to the
approach being used by others to develop novel AKR1C3 inhi-
bitors based on the structure of indomethacin.
8-10 Finally, since
a variety of NSAIDs inhibit AKR1C3,
11,40-43 future studies
shouldaddress whether thechemopreventiveactionsofNSAIDs
reported inanumberofcancers
44-47includederegulationofthe
TCA cycle in premalignant cells.
’METHODS
Cell Culture Conditions. KG1a and K562 AML cell lines were
maintained in exponential proliferation in RPMI 1640 medium (Gibco-
Invitrogen) with 10% fetal bovine serum (FBS, Gibco-Invitrogen) and
100 units mL
-1 of penicillin and 100 μgm L
-1 of streptomycin (Gibco-
Invitrogen). The cells were cultured in a humidified chamber at 37  C
and with 5% CO2 (nonhypoxic condition). For experiments performed
in hypoxic conditions, the cells were moved to a hypoxic chamber
(humidified at 37  C, with 1% O2 and 5% CO2) and accustomed to this
environment for 24 h prior to treatment.
Cell Treatments. Cells (5   10
7) were treated with either solvent
control (ethanol) or 20 μM indomethacin. For each treatment, 12
replicate samples were prepared for the nonhypoxic growth condition
and 6 replicate samples for the hypoxic one. After 24 h the cells were
washed with PBS (Lonza Group Ltd.) and harvested by centrifugation.
Thecellpellets wereimmediatelyfrozen inliquid nitrogenandstoredat
-80  C.
NMR Sample Preparation. The extraction of polar intracellular
metabolites from cell pellets was performed using a modified Bligh-
Dyerprocedure.
48Samplesweredriedovernightinacentrifugalvacuum
concentrator. The dried polar extracts were redissolved in 90% H2O/
10% D2O (GOSS Scientific Instruments Ltd.) prepared as 100 mM
phosphate buffer (pH 7.0), containing 0.5 mM sodium 3-(trimethyl-
silyl)propionate-2,2,3,3-d4(TMSP,CambridgeIsotopeLaboratories)as
internal reference.
NMR Experiments and Data Processing. A 500 MHz Bruker
spectrometer equipped with a cryogenically cooled probe was used for
2D
1HJ-RES
49and1D
1HNMRdataacquisition.Inbothcasesthewater
resonance was suppressed using excitation sculpting.
50
1D
1HNMRDataforQuantitative DeterminationofMetabolites. 1
Dspectrawereacquiredwithalongrelaxationdelayof15sanda30 flip
angle to guarantee near complete longitudinal relaxation. 1D spectra
were acquired with a spectral width of 5 kHz and 256 transients.
2D
1H J-RES NMR. 2D J-RES spectra were collected using a double
spinechosequencewith16transientsperincrementand32increments.
Strong coupling artifacts were suppressed by phase cycling.
51 Prior
to Fourier transformation, 2D J-RES spectra were multiplied by a174 dx.doi.org/10.1021/cb900300j |ACS Chem. Biol. 2011, 6, 169–175
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combined sine-bell/exponential window function in the direct dimen-
sion and bya sine bellfunction in the incremented dimension.
52 Skyline
projections (of the nontilted and nonsymmetricized 2D spectra) were
calculatedandthenalignedtoTMSPat0.0ppm.Selectedsignalsarising
from residual solvents and TMSP were excluded. Spectra were normal-
ized according to the probabilistic quotient method
53 and binned at
0.0015 ppm. A generalized-log transformation was applied prior to
conducting the multivariate statistical analysis.
54 Multivariate statistical
analysis (PCA) of the projected J-RES NMR data was carried out using
PLS toolbox (Version 4.1; eigenvector Research).
Multiple univariate analyses (t tests) were performed on all the data
points of
1H 1D NMR spectra after the exclusion of noise (3 times the
noise level calculated according to ref 55). The results were then false
discovery rate (FDR) corrected to signiﬁcance levels of 1% or 5%.
All the NMR data sets were processed using NMRLab
56 in the
MATLAB programming environment (The MathWorks, Inc.). NMR
resonances of metabolites were assigned and quantiﬁed using the
Chenomx NMRSuite(version5.0; ChenomxInc.).Theconcentrations
of metabolites are reported as mean values ( standard deviation. The
reported statistical signiﬁcance is based on a t test.
AssessmentofROSFormation. Carboxy-H2DCFDA(Molecular
Probes,Invitrogen)wasaddedtothecellsduringthelast30minofthe24-h
treatment period. Following incubation, cells were washed with PBS and
analyzed by flow cytometry.
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